Antiangiogenic drugs and advanced proliferative diabetic retinopathy

Ribeiro, J.A.; Messias, André; Jorge, Rodrigo

doi:10.1590/s0004-27492011000200017

Cited by 10 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current RCT or traditional meta-analysis could only conclude a pairwise comparison among these strategies. For instance, several RCTs reported that pre-operative anti-VEGF injection 5 to 10 days before PPV was clinically superior to 1 to 3 days 7 , while no RCTs compared these time-points with anti-VEGF injection at the end of PPV or other time-points; Secondly, there are too many strategies for this anti-VEGF treatment reported by current studies, regarding different anti-VEGF agents, dosages and time-points 7 , 8 .…”

Section: Introductionmentioning

confidence: 87%

Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis

Wang

Zhao

Zhang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Currently, controversies regarding the optimal time-point of anti-vascular endothelial growth factor (VEGF) pretreatment before pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR) still exist. To clarify this, we conducted a network meta-analysis, 26 randomized controlled trials including 1806 PDR patients were included. Compared with the sham group, performing anti-VEGF injection at preoperative (Pre-Op) 6 to 14 days could significantly improve post-operative best-corrected visual acuity (BCVA) and decrease the incidence of recurrent vitreous hemorrhage (VH). Meanwhile, it could significantly reduce the duration of surgery. Performing anti-VEGF injection at Pre-Op more than 14 days, 6 to 14 days or 1 to 5 days could significantly reduce the incidence of intra-operative bleeding, while no significant benefit existed at the end of PPV (P > 0.05). No significant difference existed between all those strategies and sham group in reducing the rate of silicone oil tamponade. Based on currently available evidence, performing the anti-VEGF pretreatment at pre-operative 6 to 14 days showed best efficacy in improving post-operative BCVA, reducing the duration of surgery and incidence of recurrent VH, it also achieves satisfactory effect in reducing the incidence of intra-operative bleeding.

show abstract

Section: Introductionmentioning

confidence: 87%

Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis

Wang

Zhao

Zhang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The concept of restoring altered angiogenesis as a potential therapy has seen increasingly rapid advances in many pathologies, such as cancer (Albiges et al 2011, Leite et al 2011, Sharma et al 2011, Socinski 2011, inflammatory diseases, retinopathies and agerelated macular degeneration (Bauditz & Lochs 2007, Mitchell 2011, Ribeiro et al 2011. As abnormal ovarian angiogenesis is a main feature of the PCOS, restoring this process has been proposed as a possible PCOS therapy to improve ovulation and fertility.…”

Section: Therapeutic Strategies To Restore a Correct Ovarian Angiogenmentioning

confidence: 99%

Ovarian angiogenesis in polycystic ovary syndrome

Pietro¹,

Pascuali²,

Parborell³

et al. 2018

Reproduction

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine pathology among women in reproductive age. Its main symptoms are oligo or amenorrhea, hyperandrogenism and the presence of ovarian cysts. It is also associated with infertility, obesity and insulin resistance. Mainly due to its heterogeneity, PCOS treatments are directed to manage its symptoms and to prevent associated diseases. The correct formation and regression of blood vessels during each ovarian cycle is indispensable for proper follicular development, ovulation and corpus luteum formation. The importance of these processes opened a new and promising field: ovarian angiogenesis. Vascular alterations characterize numerous pathologies, either with increased, decreased or abnormal angiogenesis. In the last years, several anomalies of ovarian angiogenesis have been described in women with PCOS. Therefore, it has been suggested that these alterations may be associated with the decreased - or lack of - ovulation rates and for the formation of cysts in the PCOS ovaries. Restoration of a proper vessel formation in the ovaries may lead to improved follicular development and ovulation in these patients. In the present review, we attempt to summarize the alterations in ovarian angiogenesis that have been described in women with PCOS. We also discuss the therapeutic approaches aimed to correct these alterations and their beneficial effects on the treatment of infertility in PCOS.

show abstract

“…Due to long-term hypoxia in the occurrence and development of PDR, secretion of VEGF by retinal cells is increased, which causes new vessel hyperplasia, vitreous hemorrhage, and fibrovascular membranes and eventually leading to the TRD and severe damage to vision or even blindness [ 27 , 28 ]. Clinical trials concluded that preoperative intravitreal injection of anti-VEGF drugs can reduce the intravitreal VEGF level, inhibit the activity of VEGF partially, and decrease retinal vascular leakage and neovascularization [ 29 , 30 ]. Anti-VEGF drugs can also reduce the incidence of bleeding and iatrogenic holes during epiretinal membrane dissection [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy

Cui

Chen

et al. 2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Introduction To compare the effect and safety of intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), or intravitreal triamcinolone acetonide (IVTA) injection on 23-gauge (23-G) pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). Methods Fifty patients (60 eyes) of varying degrees of PDR were randomly grouped into 3 groups (1 : 1 : 1) (n = 20 in each group). The 23-G PPV was performed with intravitreal conbercept or ranibizumab injection 3–7 days before surgery or intravitreal TA injection during surgery. The experiment was randomized controlled, with a noninferiority limit of five letters. Main outcome measures included BCVA, operation time, incidence of iatrogenic retinal breaks, endodiathermy rate, and silicone oil tamponade. Results At 6 months after surgery, there were no significant differences of BCVA improvements, operation time, incidence of iatrogenic retinal breaks, endodiathermy rate, silicone oil tamponade, vitreous clear-up time, and the incidence of intraoperative bleeding between the IVC and IVR groups (all P values ≥ 0.05), but they were significantly different from the IVTA group (all P values < 0.05). IOP increases did not show significant differences between the IVC and IVR groups, but both were significantly different with the IVTA group. More patients had higher postoperative IOP in the IVTA group. Conclusions The intravitreal injection of conbercept, ranibizumab, or TA for PDR had a significant different effect on outcomes of 23-G PPV surgery. Conbercept and ranibizumab can reduce difficulty of the operation, improve the success rate of PPV surgery, and decrease the incidence of postoperative complications.

show abstract

Antiangiogenic drugs and advanced proliferative diabetic retinopathy

Cited by 10 publications

References 39 publications

Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis

Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis

Ovarian angiogenesis in polycystic ovary syndrome

Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy

Contact Info

Product

Resources

About